RESUMO
Ingenol mebutate (IM) is a topical pharmacotherapy approved in Switzerland since 2012 for treating non-hypertrophic, non-hyperkeratotic actinic keratosis (AK). We report 2 cases with off-label use of IM. The first case of bowenoid AK was treated with 150 µg IM for 3 consecutive days with an almost complete clinical remission of the lesion. The second case of Bowen's disease was treated with 500 µg IM for 2 consecutive days leading to complete clinical remission.
Assuntos
Antineoplásicos/administração & dosagem , Doença de Bowen/tratamento farmacológico , Diterpenos/administração & dosagem , Ceratose Actínica/tratamento farmacológico , Neoplasias Cutâneas/tratamento farmacológico , Administração Cutânea , Idoso , Doença de Bowen/patologia , Pálpebras , Feminino , Géis , Mãos , Humanos , Ceratose Actínica/patologia , Masculino , Neoplasias Cutâneas/patologiaRESUMO
A 52-year-old Colombian woman, a patient with psoriasis, undergoing phototherapy with (ultraviolet B narrowband) UVBnb, presented with a symptomless solitary diffuse erythaematous plaque on her nose for 3â months. Initially, she was treated with pimecrolimus 1% cream for 8â weeks, which was then combined with metronidazole cream for 4â weeks, with the initial diagnosis of UV-triggered rosacea, without improvement. A punch biopsy was performed and the histology showed a pseudolymphomatous reaction. The diagnosis of nasal pseudolymphoma of borreliosis was confirmed with PCR. The lesion completely resolved following oral doxycycline therapy.